NCT01734928: Phase 3 - Safety/Efficacy of Pom Bortezomib and Low-dose Dex in relapsed MM (OPTIMISMM)
NCT01712789: Phase 3 - Pomalidomide + Dex (Low Dose) Refractory or Relapsed Multiple Myeloma STRATUS
NCT01464034: Phase 1/2 - Carfilzomib, Pomalidomide With Dexamethasone in Patients With RRMM
NCT01311687: Phase 3 - Efficacy & Safety of Pomalidomide & Low dose dex Vs High-Dose Dex - NIMBUS
NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
NCT01421524: Phase 1: Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness
NCT01081028: Connect® MM- The Multiple Myeloma Disease Registry
NCT01239797: Phase 3: Lenalidomide and Dexamethasone With or Without Elotuzumab RRMM (ELOQUENT - 2)
NCT01191060: Phase 3 - IFM 2009 - (IFM/DFCI2009) Conventional dose RVD to High-Dose + ASCT -NDMM
NCT01029054: Phase 1/2: Carfilzomib and Lenalidomide With Dexamethasone Combination in NDMM
NCT00833833: Phase 1/2: MTD, Safety, and Efficacy of Pomalidomide (CC-4047) +/- Dexamethasone RRMM
NCT00689936: Phase 3 - Lenalidomide+low dose dex vs Melphalan, Prednisone, Thalidomide in NDMM FIRST
NCT00430365: Phase 3 - IFM2005-02 - Maintenance Therapy Using Lenalidomide in Myeloma
NCT00424047: Phase 3 - CC-5013 (lenalidomide) Dex Vs Dex Alone Previously Treated Multiple Myeloma
NCT00480363: Phase 3: Revlimid / Dex ( ReDex) VS Observation in Smoldering MM (QUIREDEX)
NCT00378105: Phase 1/2: Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in NDMM
NCT00405756: Phase 3 - A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects
NCT00083551: UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma
NCT00056160 : Phase 3 - CC-5013 (lenalidomide) Dex Vs Dex Alone Previously Treated Multiple Myeloma